news
MHRA approves Epidyolex® (cannabidiol) for TSC seizure treatment
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
List view / Grid view
clobazam
news
Epidyolex (cannabidiol) reclassified as Schedule 5 in UK, relaxing control over drug
GW Pharmaceuticals's Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
news
Epidyolex available to patients through the NHS from today
Epidyolex, which contains cannabidiol, can now be prescribed by doctors to epilepsy patients in the UK through the NHS.
news
EPIDYOLEX® receives marketing authorisation in Europe
The cannabidiol-based treatment EPIDYOLEX has been granted marketing authorisation from the European Commission.
news
NICE to work with GW Pharma on cannabidiol evaluation
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
news
Cannabidiol-based treatment receives marketing approval from EMA
EMA’s human medicines committee had cleared the cannabidiol oral solution, Epidiolex, for use to treat seizures.
news
Compound derived from marijuana interacts with antiepileptic drugs
Cannabidiol is being studied as a potential anticonvulsant, and it has demonstrated effectiveness in animal models of epilepsy and in humans...
